Literature DB >> 16517387

Minimally invasive, extracavitary approach for thoracic disc herniation: technical report and preliminary results.

Zvi Lidar1, Jason Lifshutz, Sumon Bhattacharjee, Shekar N Kurpad, Dennis J Maiman.   

Abstract

BACKGROUND: Traditional approaches to thoracic disc herniation are technically demanding and, if incorporating thoracotomy, can be associated with significant morbidity. New procedures have allowed discectomy with less pain and morbidity.
PURPOSE: To assess the feasibility, safety, and early outcome of a minimally invasive extracavitary approach (MI-ECA) for thoracic disc disease. STUDY
DESIGN: Cadaver sessions and a short-term human study were performed on four cadavers and 10 patients, respectively. Operative results and complications were studied, and early outcome was assessed using a Visual Pain Analog Scale, neurological status, and American Spinal Injury Association (ASIA) classification.
METHODS: Four fresh cadaver sessions, attempting all thoracic levels, were completed to determine the feasibility of the technique. Ten patients with thoracic myelopathy caused by herniated disc were treated using the minimally invasive extracavitary approach.
RESULTS: Intervertebral discs were successfully removed from all four cadavers using this procedure. No operative complications in the human series were documented. The mean operative time was 171 minutes (150-220), mean estimated blood loss was 215 cc (60-350), and hospital stay for all patients was one night. No operative or postoperative complications were encountered. All patients returned to work within 4 weeks after discharge. Postoperative ASIA scores improved in three patients who had motor or sensory findings. Tone improved in all patients. Mean pain outcome using the Visual Pain Analog Scale was 1.5 (0-3).
CONCLUSION: Our early experience suggests that MI-ECA may be a valuable option in the management of thoracic disc herniation.

Entities:  

Mesh:

Year:  2006        PMID: 16517387     DOI: 10.1016/j.spinee.2005.05.377

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  7 in total

1.  Extreme Lateral Interbody Fusion (XLIF) in the Thoracic and Thoracolumbar Spine: Technical Report and Early Outcomes.

Authors:  Dennis S Meredith; Christopher K Kepler; Russel C Huang; Vishal V Hegde
Journal:  HSS J       Date:  2013-01-25

2.  Surgical treatment of thoracic disc herniations via tailored posterior approaches.

Authors:  Wolfgang Börm; U Bäzner; R W König; T Kretschmer; G Antoniadis; J Kandenwein
Journal:  Eur Spine J       Date:  2011-04-29       Impact factor: 3.134

3.  Thoracoscopic Microdiscectomy with Preservation of Rib and Costovertebral Joint.

Authors:  E M J Cornips; E A M Beuls
Journal:  Adv Tech Stand Neurosurg       Date:  2022

4.  Oxygen-Ozone Therapy Associated with Alpha Lipoic Acid Plus Palmitoylethanolamide and Myrrh versus Ozone Therapy in the Combined Treatment of Sciatic Pain Due to Herniated Discs: Observational Study on 318 Patients.

Authors:  Matteo Bonetti; Dorina Lauritano; Gian Maria Ottaviani; Alessandro Fontana; Alessio Zambello; Luigi Della Gatta; Mario Muto; Francesco Carinci
Journal:  Int J Environ Res Public Health       Date:  2022-05-07       Impact factor: 4.614

5.  Suitability of Administrative Databases for Durotomy Incidence Assessment: Comparison to the Incidence Associated With Bone-Removal Devices, Calculated Using a Systemic Literature Review and Clinical Data.

Authors:  Robert Pflugmacher; Angelo Franzini; Shaked Horovitz; Richard Guyer; Ely Ashkenazi
Journal:  Int J Spine Surg       Date:  2018-08-31

6.  Endoscopic transforaminal thoracic foraminotomy and discectomy for the treatment of thoracic disc herniation.

Authors:  Hong-Fei Nie; Kai-Xuan Liu
Journal:  Minim Invasive Surg       Date:  2013-12-18

7.  Full-endoscopic interlaminar discectomy for the treatment of a dorsal migrated thoracic disc herniation: Case report.

Authors:  Jung-Woo Hur; Jin-Sung Kim; Ji-Hoon Seung
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.